MPS Limited FY26 EBITDA ₹236 Cr, Guides ₹300+ Cr for FY27

MPS Limited reported audited FY26 results with record EPS of ₹102.11, up 16.3% YoY, and EBITDA of ₹236 Cr, up 11.8% YoY.
The company acquired Unbound Medicine in Feb 2026, expanding into healthcare knowledge and contributing to Education segment revenue growth of 30.55% YoY.
MPS provided strong FY27 guidance targeting EBITDA exceeding ₹300 Cr, representing a 3-year CAGR of ~21%, supported by a refocused GTM strategy and AI product integration.
The Research segment remained the profit anchor with a 39.9% EBITDA margin, while Corporate Learning EBITDA rebounded 55.45% QoQ after a strategic cost reset.